Opdivo

News

BMS and Roche look to Halozyme drug delivery for IO advantag...

Bristol-Myers Squibb is to work with drug delivery specialist Halozyme to create an injectable form of its blockbuster immunotherapy Opdivo.

News

Clovis and BMS combine cancer drugs in late-stage trials

Clovis and BMS research small molecule and antibody combination.

News

Scotland decision helps Opdivo in UK market access picture

The last 18 months has seen groundbreaking cancer immunotherapies, led by BMS’s Opdivo and Merck Sharp & Dohme’s Keytruda hit the UK market, with both rapidly adding multiple indication

News

BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cance...

Bristol-Myers Squibb is teaming up with France’s Transgene to combine Opdivo with investigational therapeutic vaccine TG4010 in lung cancer.

News

NICE rejects Opdivo in head and neck cancer – before it gain...

England and Wales’ cost effectiveness watchdog NICE has rejected Opdivo for use against advanced head and neck cancer in draft guidance – before the drug has even been given final Euro

News